Rodman & Renshaw initiated coverage on shares of CytoDyn Inc. (OTC:CYDY) in a report issued on Thursday morning, StockTargetPrices.com reports. The brokerage issued a buy rating and a $1.60 price objective on the stock.
Shares of CytoDyn (OTC:CYDY) opened at 0.71 on Thursday. The firm’s market cap is $88.42 million. The stock’s 50 day moving average is $0.84 and its 200-day moving average is $1.04. CytoDyn has a 52-week low of $0.63 and a 52-week high of $1.57.
CytoDyn Company Profile
CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.
Receive News & Ratings for CytoDyn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.